Pharmaceuticals, Biotechnology & Life Sciences

Johnson & Johnson’s latest legal battles, Blackstone partnership, and TREMFYA data reveal a resilient portfolio and rising analyst targets, keeping investors confident in its future growth.

Ocugen’s clinical‑stage biopharma journey: regenerative joint therapy, 2026 stock trends, upcoming earnings call, and investor outlook for biotech growth.

Discover how AQST’s delayed CNS drug approval and legal scrutiny shape its valuation and investor confidence, and what the upcoming Oppenheimer conference could mean for its future.

Ardelyx’s latest earnings reveal a biotech firm focused on GI‑centric metabolic drugs, trading at $5.73 with a $1.41B market cap and high investor confidence.

Arvinas Inc. gears up for a Q4 2025 earnings report, engaging investors via conferences and positioning itself in the $4.53 bn targeted protein degradation market poised for 32% CAGR growth to 2033.

Harmony Biosciences wins FDA approval for WAKIX in pediatric narcolepsy, boosting its market and offering new hope for young patients.

MoonLake Immunotherapeutics reports >80% ASAS40 response in Phase‑2 axSpA study, driving shares above $20 and boosting confidence in its Sonelokimab pipeline and 2025 financial outlook.

Tenaya Therapeutics is a biotech firm focused on curative therapies for heart disease, offering investors insight into its 2026 goals, market performance, and future potential.

Charlotte’s Web Holdings, a Boulder‑based cannabis‑infused wellness pioneer, showcases volatile stock, negative earnings, and high P/B—an intriguing watch for investors.

Discover ADC Therapeutics’ progress in antibody‑drug conjugate oncology—Swiss‑based, US‑focused, volatile stock, and its commitment to innovative cancer treatments.